Cover Image

醫療事務相關評價 (歐洲主要5個國家):帕金森氏症

Medical Affairs Reputations (EU5) [Parkinson's Disease]

出版商 FirstWord 商品編碼 581393
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
醫療事務相關評價 (歐洲主要5個國家):帕金森氏症 Medical Affairs Reputations (EU5) [Parkinson's Disease]
出版日期: 2017年10月01日 內容資訊: 英文

本報告以歐洲主要5個國家 (EU5:法國·德國·義大利·西班牙·英國) 從事帕金森氏症治療藥開發的醫療團隊為焦點,提供醫生和醫療團隊間的互動性,及主要接觸方法,不同團隊間的業績競爭性評估,今後應該改善項目等相關調查。


  • Apokinon (apomorphine SC; Britannia)
  • Azilect (rasagiline; Teva/Lundbeck)
  • Comtan (entacapone; Novartis)
  • Dostinex (cabergoline; Pfizer)
  • Duodopa (levodopa/carbidopa intraduodenal; AbbVie)
  • Neupro (rotigotine; UCB)
  • Requip (ropinirole; GSK)
  • Tasmar (tolcapone; Meda Pharma)
  • Xadago (safinamide; Zambon)


第1章 調查目的·手法·樣品採取,分析目標產品,摘要整理

第2章 醫療團隊間的相互關係現況

  • 各產品方面,最近6個月平均每月醫療團隊間的互動
  • 各產品方面,醫療團隊間的互動頻率

第3章 醫療團隊的業績競爭評估

  • 各產品方面,醫療團隊間的互動
  • 醫療團隊在醫生臨床治療上所扮演的角色:重要性程度
  • EdgeMap分析:醫療團隊的業績競爭性評價
  • 醫師對醫療事務團隊互動滿意度的競爭性評價
  • 需求·差距分析:各產品

第4章 受歡迎的互動方式,頻率和改進建議

第5章 附錄


How well does your Parkinson's Disease medical affairs team performance compare with the rest?

According to this latest survey of 150 neurologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of Parkinson's Disease medical affairs teams still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.

Use Medical Affairs Reputations: Parkinson's Disease 2017 (EU5) to discover how your team can better meet the high expectations of physicians at the frontline.

This report compares the current activities of medical affairs teams for the 9 leading treatments for Parkinson's Disease from AbbVie, Britannia, GSK, Lundbeck, Meda Pharma, Novartis, Teva, UCB and Zambon. It shows:

  • How physicians rate each team overall, and for 12 key medical affairs services.
  • What is most important to physicians, plus what can be done better.
  • How, and how often physicians want to meet with your team.

It's time to find out exactly how well your medical affairs team is performing against fierce competition - and establish an action plan to gain competitive advantage.

Interested in the US market? Click here to see the US Edition.

Request sample pages

Top Takeaways

  • One clear winner, but plenty to play for. Four teams visit over two thirds of physicians, with one a full 10 points clear in the lead; is this your team? If not, what can you do to gain ground?
  • Building confidence. How much do European physicians rely on medical affairs to answer questions about off-label usage? What are they spending more time talking about to medical affairs professionals than ever before?
  • How are the new kids on the block faring against the old guard? New brands on the market are benchmarked against established therapies, but how are they doing? Is it a case of not enough time on the market, or are they proactively shaping physician sentiment?
  • Are patients the main focus, or is it something else? How much do European physicians rely on medical affairs to help them improve patient access, education and outcomes? And are they spending more or less time doing this than before?
  • Information or attitude? When it comes to what physicians recommend in terms of key areas for improvement, is it information, attitude or something else? Could addressing these tip the balance?

Insight into Medical affairs teams for these Parkinson's Disease treatments

  • Apokinon (apomorphine SC; Britannia)
  • Azilect (rasagiline; Teva/Lundbeck)
  • Comtan (entacapone; Novartis)
  • Dostinex (cabergoline; Pfizer)
  • Duodopa (levodopa/carbidopa intraduodenal; AbbVie)
  • Neupro (rotigotine; UCB)
  • Requip (ropinirole; GSK)
  • Tasmar (tolcapone; Meda Pharma)
  • Xadago (safinamide; Zambon)

A Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of medical affairs teams for 9 leading Parkinson's Disease brands-answering important questions like:

What do physicians need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practising Physicians

We surveyed 150 neurologists from the EU5 (France, Italy, Germany, Spain, UK) chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 Parkinson's Disease patients a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the past 6 months.

We conducted the survey between October 9-25, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at

Table of Contents

1. Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary

2. Current Status of Interactions with Different Medical Affairs Teams

  • 2.1 Interactions in the past 6 months with Medical Affairs teams for each product
  • 2.2 Current frequency of interactions with medical affair teams for each product

3 Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes

  • 3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
  • 3.2 Attribute importance of Medical Affairs teams roles to physicians' practice
  • 3.3 EdgeMap analysis - Competitive evaluation on Medical Affairs teams performance on attributes
  • 3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
  • 3.5 Need-Gap analysis by product

4 Preferred Interaction Media, Frequency, and Suggestions for Improvement

  • 4.1 Preferred interaction media and frequency, and suggestions for improvement

5 Appendix

Back to Top